|
Mar 1
|
Cytokinetics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
|
Feb 28
|
Cytokinetics Q4 Loss Wider Than Expected, Aficamten in Focus
|
|
Feb 28
|
Q4 2024 Cytokinetics Inc Earnings Call
|
|
Feb 28
|
Cytokinetics Inc (CYTK) Q4 2024 Earnings Call Highlights: Revenue Surge Amidst Rising Expenses
|
|
Feb 27
|
Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates
|
|
Feb 27
|
Cytokinetics: Q4 Earnings Snapshot
|
|
Feb 27
|
Cytokinetics Reports Fourth Quarter 2024 Financial Results and Provides Business Update
|
|
Feb 23
|
Cytokinetics, Incorporated (CYTK): the Most Oversold Pharma Stock to Buy According to Analysts
|
|
Feb 20
|
Cytokinetics, Incorporated (CYTK): One of the Most Oversold Healthcare Stocks to Buy Now
|
|
Nov 12
|
Cytokinetics to Participate in the 2024 Jefferies London Healthcare Conference
|
|
Nov 11
|
Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4015089
|
|
Nov 8
|
Cytokinetics Third Quarter 2024 Earnings: Misses Expectations
|
|
Oct 16
|
Is Cytokinetics Inc. (CYTK) the Most Promising Biotech Stock According to Hedge Funds?
|
|
Oct 16
|
Cytokinetics Highlights Progress in Cardiac Myosin Modulation Programs and Global Commercial Launch Readiness at Investor & Analyst Day
|
|
Oct 2
|
Cytokinetics to Host Investor & Analyst Day on October 16, 2024
|
|
Oct 1
|
Is Cytokinetics Inc. (CYTK) Positioned for Success with Its Innovative Muscle Modulators?
|
|
Sep 30
|
Cytokinetics Presents Additional Data From SEQUOIA-HCM at the HFSA Annual Scientific Meeting
|
|
Sep 27
|
Cytokinetics Presents Additional Data from SEQUOIA-HCM at the HCMS Scientific Sessions
|
|
Jul 30
|
Investors in Cytokinetics (NASDAQ:CYTK) have seen incredible returns of 381% over the past five years
|
|
Jul 30
|
Cytokinetics Announces Call for Proposals for Corporate Giving Program
|